BA Read More

Problem: Despite being a global leader in generic pharma, India relies heavily on China for 65%-100% of APIs, posing economic and political risks. Chinese firms dominate due to aggressive scaling, price advantages (10%-20% lower), and entrenched vendor relationships, making it difficult for Indian API players to compete. Solution: A two-pronged strategy can be implemented:<ol style="list-style-type:decimal;"><li>Rapid R&D to target new off-patent or low-competition APIs, reduce development lead times, and secure formulation partnerships early.</li><li>Improve operational efficiency by eliminating capacity wastage, optimizing production flow, and offering shorter lead times to customers.</li></ol> Benefits: This strategy enables API players to increase output (30%-40%), reduce WIP (40%), shorten working capital cycles, and enhance price competitiveness. Reliable supply and ready delivery help gain market share, making India a globally competitive API hub.

Key Takeaways

API manufacturing in India is less attractive than in China. However, by enhancing operational excellence in manufacturing and R&D, India's API industry can unleash its true potential.

Mighty molecules: Strategies for reclaiming the global API throne

Download PDF

Explore strategies for India to reduce dependency on Chinese APIs and regain leadership in global pharmaceutical manufacturing. Read more insights from Vector Consulting Group.